Table 1 Characteristics of patients treated with ruxolitinib and matched control group treated with dexamethasone
Names | Reference arm (n = 146) | Treatment arm (n = 146) | p-value |
|---|---|---|---|
Age, years, mean ± SD | 58 ± 12.9 | 58.1 ± 13.3 | 0.93 |
Gender | F: 64 (43.8%) M: 82 (56.2%) | F: 66 (45.2%) M: 80 (54.8%) | 0.81 |
Body mass index, mean ± SD | 30.7 ± 13.4 | 30.4 ± 5.6 | 0.81 |
Day of illnes | 7.4 ± 4.3 | 7.5 ± 4.3 | 0.87 |
Admission creatinine, mmol/L | 0.1 ± 0 | 0.1 ± 0 | 0.67 |
Admission CRP, mg/L | 99.5 ± 84.7 | 97.4 ± 71.9 | 0.82 |
Maximal CRP, mg/L | 105.2 ± 80.6 | 101.1 ± 86.4 | 0.68 |
Admission ferritin, ng/mL | 646 ± 538.3 | 617 ± 403.8 | 0.6 |
Maximal glucose, mmol/L | 7.7 ± 2.7 | 7.6 ± 2.9 | 0.71 |
Maximal temperature, °C | 38.1 ± 0.8 | 38.1 ± 0.9 | 0.77 |
Mean lymphocytes, 109/L | 1.2 ± 0.5 | 1.3 ± 0.8 | 0.074 |
Mean monocytes, 109/L | 0.4 ± 0.2 | 0.5 ± 0.3 | 0.41 |
Mean neutrophils, 109/L | 5.3 ± 3.8 | 5.1 ± 3.1 | 0.72 |
Mean potassium, mmol/L | 4 ± 0.4 | 4 ± 0.5 | 0.95 |
Mean sodium, mmol/L | 138.7 ± 3.4 | 138.6 ± 3.8 | 0.83 |
Mean WBC, 109/L | 6.9 ± 3.8 | 6.8 ± 3.2 | 0.79 |
Admission hemoglobin, g/L | 133.5 ± 18.7 | 134.4 ± 19 | 0.69 |
Minimal platelets, 109/L | 202.2 ± 68.9 | 201.1 ± 64.2 | 0.89 |
Admission SpO2, % | 93.7 ± 2.3 | 93.6 ± 3.2 | 0.74 |
Minimal SpO2, % | 93.8 ± 3.3 | 93.5 ± 4.6 | 0.43 |
Cardiovascular disease | Yes: 75 (51.4%) No: 71 (48.6%) | Yes: 73 (50%) No: 73 (50%) | 0.82 |
Diabetes | Yes: 33 (22.6%) No: 113 (77.4%) | Yes: 29 (19.9%) No: 117 (80.1%) | 0.57 |
HIV | Yes: 2 (1.4%) No: 144 (98.6%) | Yes: 1 (0.7%) No: 145 (99.3%) | 0.56 |
Chronic liver disease | Yes: 5 (3.4%) No: 141 (96.6%) | Yes: 5 (3.4%) No: 141 (96.6%) | 1 |
Oncological disease not in remission | Yes: 7 (4.8%) No: 139 (95.2%) | Yes: 9 (6.2%) No: 137 (93.8%) | 0.61 |
Chronic respiratory disease | Yes: 11 (7.5%) No: 135 (92.5%) | Yes: 17 (11.6%) No: 129 (88.4%) | 0.23 |
Tuberculosis in the patient’s history | Yes: 4 (2.7%) No: 142 (97.3%) | Yes: 3 (2.1%) No: 143 (97.9%) | 0.7 |
Severity of lung injury based on computed tomography | CT-1: 16 CT-2: 83 CT-3: 47 | CT-1: 20 CT-2: 97 CT-3: 29 | 0.058 |
Additional antibiotic therapy | Yes: 128 (88%) 69 (54%)—azithromycin 10 (8%)—beta-lactam antibiotics 10 (8%)—fluorchinolone 38 (30%)—antibacterial combinationa No: 18 (12%) | Yes: 137 (94%) 40 (29%)—azithromycin 15 (11%)—beta-lactam antibiotics 9 (7%)—metronidazole 73 (53%)—antibacterial combinationb No: 9 (6%) | 0.105 |